COVID-19: CDC, FDA and CMS Guidance

This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.

The Food and Drug Administration authorized a revised dosing regimen for the combination monoclonal antibody therapy Evusheld when used to prevent COVID-19 in certain patients, citing data showing a higher initial dose may better prevent infection by certain omicron subvariants.
The Centers for Disease Control and Prevention said some people may wish to receive their second dose of the Pfizer or Moderna COVID-19 vaccine up to eight weeks after the first, especially males aged 12 to 39.
The Centers for Medicare & Medicaid Services has released Medicare payment codes effective Feb. 11 for administering the monoclonal antibody bebtelovimab, effective against the omicron COVID-19 variant.
The Food and Drug Administration announced a Class 1 recall of the E25Bio COVID-19 Direct Antigen Response Test, which was marketed and distributed to U.S. customers without authorization or approval.